Posted by Michael Wonder on 26 Jul 2023
Afamelanotide acetate for the treatment of patients with erythropoietic protoporphyria
27 July 2023 - NICE has published final evidence-based recommendations on the use of afamelanotide acetate (Scenesse) for the treatment of adults with erythropoietic protoporphyria.
Afamelanotide acetate is not recommended for the prevention of phototoxicity in adults with erythropoietic protoporphyria.
